Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia
10.3971/j.issn.1000-8578.2026.25.0749
- VernacularTitle:CAR-NK疗法在急性髓系白血病中的应用研究进展
- Author:
Shuai SU
1
;
Yi XIAO
1
Author Information
1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:REVIEWS
- Keywords:
Acute myeloid leukemia;
Natural killer cell;
Immunotherapy;
CAR-NK
- From:
Cancer Research on Prevention and Treatment
2026;53(4):281-288
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR) T-cell therapy for B-cell hematologic malignancies has achieved breakthrough success; however, its efficacy for acute myeloid leukemia (AML) is constrained by the lack of highly specific tumor antigens and the expression of shared targets on normal hematopoietic stem/progenitor cells, increasing the risk of on-target myelosuppression and cytokine release syndrome (CRS). By contrast, CAR-NK cell therapy, an emerging strategy that leverages the innate antitumor activity of natural killer cells, is associated with low rates of CRS and graft-versus-host disease. Early clinical studies also indicate its favorable safety profile with preliminary antileukemic activity. This review summarizes recent advances in CAR-NK therapy for AML and discusses future directions and potential avenues for clinical translation.
